AMP Capital Investors’s Maravai LifeSciences MRVI Stock Holding History

AMP Capital Investors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-24,608	Closed	-$1.21M	–	693
2021 Q3	$1.21M	Hold	24,608	–	–	0.01%	810
2021 Q2	$1.03M	Sell	24,608 -39,739	-62%	-$1.54M	﹤0.01%	844
2021 Q1	$2.29M	Buy	64,347 +11,658	+22%	+$386K	0.01%	746
2020 Q4	$1.47M	Buy	+52,689	New	+$1.47M	0.01%	795

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

AMP Capital Investors's MRVI Position: Q4 2021 in Review

AMP Capital Investors sold out of Maravai LifeSciences (MRVI) in Q4 2021, closing a stake of 24,608 shares — an estimated $1.21M sold.

AMP Capital Investors first reported a position in MRVI in Q4 2020 and held it in 4 quarters. The position peaked at $2.29M in Q1 2021. 229 funds tracked by Wall St. Rank hold MRVI as of Q4 2021.

AMP Capital Investors reported no remaining Maravai LifeSciences position as of Q4 2021 after selling out during the quarter.
AMP Capital Investors sold 24,608 Maravai LifeSciences shares in Q4 2021, an estimated $1.21M.
AMP Capital Investors first reported a position in Maravai LifeSciences in Q4 2020 and held it in 4 quarters.
AMP Capital Investors's Maravai LifeSciences position peaked at $2.29M in Q1 2021.
229 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2021.

Based on AMP Capital Investors's 13F filing for Q4 2021, filed 14 Feb 2022.